Pages that link to "Item:Q4670477"

The following pages link to Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities (Q4670477):

Displaying 47 items.

• Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach (Q93669) (← links)
• Incoherent dose-escalation in phase I trials using the escalation with overdose control approach (Q725696) (← links)
• Stochastic approximation and modern model-based designs for dose-finding clinical trials (Q903289) (← links)
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials (Q903293) (← links)
• Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials (Q1929691) (← links)
• A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes (Q2057378) (← links)
• A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering (Q2170396) (← links)
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity (Q2441853) (← links)
• Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
• Cumulative cohort design for dose-finding (Q2455719) (← links)
• A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients (Q2861803) (← links)
• Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes (Q2861956) (← links)
• Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial (Q2931051) (← links)
• Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology (Q3078865) (← links)
• Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials (Q3078908) (← links)
• On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance (Q3078934) (← links)
• A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method (Q3079010) (← links)
• Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes (Q3183237) (← links)
• Joint modelling of recurrence and progression of adenomas: a latent variable approach (Q3413103) (← links)
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
• Risk-Group-Specific Dose Finding Based on an Average Toxicity Score (Q3576932) (← links)
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities (Q4670477) (← links)
• Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (Q5050425) (← links)
• Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment (Q5051094) (← links)
• Impact of different model structure and prior distribution in continual reassessment method (Q5087922) (← links)
• The adaptive accelerated biased coin design for phase I clinical trials (Q5124969) (← links)
• Ethical issues in oncology biostatistics (Q5424159) (← links)
• A weighted zero-inflated Poisson model for estimation of recurrence of adenomas (Q5425035) (← links)
• Dynamic Comparison of Kaplan–Meier Proportions: Monitoring a Randomized Clinical Trial with a Long‐Term Binary Endpoint (Q5450474) (← links)
• Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent (Q5714615) (← links)
• Target toxicity design for phase I dose-finding (Q5880075) (← links)
• DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses (Q6068878) (← links)
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
• Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review (Q6577811) (← links)
• A simulation-free approach to assessing the performance of the continual reassessment method (Q6617412) (← links)
• Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials (Q6618310) (← links)
• CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome (Q6625779) (← links)
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (Q6627253) (← links)
• Seamless phase I/II design for novel anticancer agents with competing disease progression (Q6627954) (← links)
• Early completion of phase I cancer clinical trials with Bayesian optimal interval design (Q6628100) (← links)
• TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy (Q6628336) (← links)
• Extending the continual reassessment method to accommodate step-up dosing in phase I trials (Q6628516) (← links)
• Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression (Q6629418) (← links)
• Dose finding studies for therapies with late-onset toxicities: a comparison study of designs (Q6629421) (← links)
• A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules (Q6629855) (← links)
• Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer (Q6636217) (← links)